Mineralys (MLYS) CMO exercises options and logs 10b5-1 sale at $12.93 avg
Rhea-AI Filing Summary
Mineralys Therapeutics insider activity: Dr. David Malcom Rodman, the company's Chief Medical Officer, exercised options and sold common stock under a Rule 10b5-1 plan. On 08/12/2025 he exercised stock options to acquire 6,349 shares at an exercise price of $1.08, increasing his direct beneficial ownership to 104,256 shares. The related option grants vesting details are stated: 25% vested on 07/12/2022 with the remainder vesting in 36 monthly installments. On 08/13/2025 he sold 11,365 shares at a weighted-average price of $12.9333, with sale prices ranging from $12.590 to $13.223. The transactions were effected pursuant to a 10b5-1 trading plan adopted on 10/25/2024.
Positive
- 10b5-1 plan disclosed with adoption date (10/25/2024), indicating trades were pre-planned and documented
- Option exercise clearly reported: 6,349 options exercised at $1.08, and vesting schedule disclosed
Negative
- Insider sold 11,365 shares reducing direct holdings to 92,891 shares, which increases available float
- Weighted-average sale price disclosed ($12.9333) with sales across a range ($12.590–$13.223), indicating realized insider liquidity
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan; transactions are routine but relevant to share supply.
The exercise of 6,349 options at $1.08 added shares to the reporting person's direct holdings, while the subsequent sale of 11,365 shares at a weighted-average of $12.9333 reduced his position to 92,891 shares. Because the sales were made under a Rule 10b5-1 plan adopted on 10/25/2024, they reflect pre-planned disposition rather than ad hoc market timing. The disclosed sale price range ($12.590 to $13.223) and the option vesting schedule provide clarity on timing and potential dilution from option exercises.
TL;DR: Transactions are transparent and accompanied by required 10b5-1 disclosure; governance controls appear followed.
The Form 4 discloses adoption date of the 10b5-1 plan and provides a weighted-average sale price with an offer to supply per-trade details on request, which supports compliance and transparency. The signature by attorney-in-fact and inclusion of vesting terms for the option indicate proper procedural documentation. These disclosures allow investors to assess insider selling while distinguishing planned sales from opportunistic trades.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 11,365 | $12.9333 | $147K |
| Exercise | Stock Option | 6,349 | $0.00 | -- |
| Exercise | Common Stock | 6,349 | $1.08 | $7K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.590 to $13.223. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The stock option vested as to 25% of the underlying shares on July 12, 2022, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
